BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

One new mission involves collecting Purple Pumpkins spread across the map. However, due to the area's vastness, acquiring all 25 of them can be quite a challenge. To help you complete the quest ...

DWF Labs, a crypto trading firm, said it fired one of its partners following social media allegations that one of its employees had spiked a woman's drink at a Hong Kong bar. In a press release ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ProPhet, Newest Startup Launched by Israel-Based Venture Studio, Aims to Reduce Time and Cost of Finding Molecules for New Drug Targets ProPhet was formed following AION Labs' startup challenge ...

2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO September 19 ...

Robust debuts by drug developers Bicara Therapeutics , MBX Biosciences, BioAge Labs and Upstream Bio are also encouraging potential candidates in the sector to move ahead with their listings. Septerna ...

Source: BioAge Labs, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get ...

A host of polls and surveys tell us many voters feel like Oberstar, especially in states like Wisconsin that are often termed “purple ... is the Ideas Lab Editor/Director of Community ...